CD44 and breast cancer: We have shown that loss of WISP2 expression in breast cancer cells leads to acquisition of the CD44+/CD24− phenotype, ALDH+ expression, upregulation of the ABCC2 drug efflux pump expression known to be associated with less differentiated cells and stem cells [58], although they lack SP cells.